Augmedics Announces U.S. Launch of xvision, First Augmented Reality Surgery Guidance System
Augmedics, a pioneer in augmented reality surgical image guidance, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. launch of its
Novelstem Increases Newstem Ownership to 27.3%
Following achievement of an important milestone for Stem-Cell based cancer treatments resistance diagnostics, Jerusalem based NewStem received a further $ 1 million follow-on investment from
Fat Melting Pharmaceutical Company Raziel Therapeutics Raises $22 Million
Raziel Therapeutics a clinical-stage pharmaceutical company announces a $22 million Series C preferred stock financing led by Pontifax, with the participation of existing investors Dr. Shmuel Cabilly
Concenter Biopharma Ltd. is developing a Promising Drug for Treating and Preventing Type 2 Diabetes (T2D)
Concenter Biopharma is working on a novel drug to eliminate type 2 diabetes with no side effects. The drug dramatically lowers insulin resistance, the major
SaliStick of Salignostics-the World’s First Saliva Rapid Pregnancy Test at Medica Expo, Germany
During the MEDICA exhibition in Düsseldorf, Germany, on November 18, Salignostics present for the first time the world’s first saliva rapid pregnancy test, the SaliStick. Salistick provides
Entera Bio recently entered into a $270 million license agreement with Amgen
Entera Bio‘s platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability. By transforming injectable
Pepticom Raises $5 million in Series A Funding
Jerusalem based Pepticom, a leader in artificial intelligence peptide drug discovery, has secured $5 million in Series A funding from the Chartered Group. Pepticom’s unique
Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel
Jerusalem-based Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and Swiss Lonza (SWX: LONN), an integrated healthcare solutions provider, have entered into a strategic
Accellix signs Co-Development Agreement with Orgenesis
Agreement Integrates Accellix’s Proprietary Quality Control Optic System, Cartridges, Reagents and Software into Orgenesis’ Point of Care Cellular Therapy Platform Orgenesis Inc. a leading cell